Is BNP assay useful for the diagnosis of acute dyspnea in emergencies departments?

##plugins.themes.academic_pro.article.sidebar##

Published Sep 25, 2013
Download
pdf
Vol. 91 No. 9 (2013): Issue Sep 2013

##plugins.themes.academic_pro.article.main##

Rim Lakhdhar
Chokri Hamouda
Lotfi Ben Ammar
Kamel Majed
Fekih Moncef
Naziha Kâabachi
Habiba Drissa
Nèbiha Borsali Falfoul

Abstract

Background: It would be interesting to the emergency doctor to have at his disposal a helpful diagnostic tool like brain natriuretic peptide (BNP). Such assay is simple, available and reliable.
aims: To report our experience on the role of BNP in the etiological diagnosis of acute dyspnea (AD) in emergency room (ER) and to assess the cost-effectiveness ratio of such diagnosis strategy.
methods: A prospective study conducted in the ER of Rabta university teaching hospital of Tunis, from March 1st to June 20th 2010, involving 30 consecutive patients presenting to the emergency for AD. All patients underwent echocardiography in their acute phase and benefited from the dosage of BNP during the first 4 hours. The echocardiography parameters were collected by a single operator who was unaware of the results of the BNP dosage.
results: The mean age of patients was 72.8years with a sex ratio of 1.5. AD was of orthopnea type in 9 cases and stage III NYHA dyspnea in the other patients. Clinical and radiological signs of left heart failure were noted in 30% of cases. Ultrasound data have objectified systolic dysfunction in 4 cases, diastolic in 3 cases and systolic plus diastolic in 10 cases. The BNP levels were below 100 pg/ml in 10 cases with pulmonary origin of the AD. A BNP level between 100 and 400 pg/ml was noted in 3 cases. In our study, the clinical probability of AHF prior to performing the test was estimated at 53% and estimated at 100% after the BNP assay. The BNP assay has reduced the length of stay in the emergency department 4 to 5 days and saved nearly 50% of the cost of care per patient.
Conclusion: The BNP assay, has allowed us to confirm the AHF all cases. Given the prognostic value and economic benefit of this test we recommend its use in ER of our country.

Keywords:

Emergency triage; Elderly; Brain Natriuretic Peptide; Acute heart failure

##plugins.themes.academic_pro.article.details##

References

  1. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2000; 35: 1628-37.
  2. Ray P, Arthaud M, Lefort Y, et al. Intérêt du dosage du BrainNatriuretic Peptide (BNP) dans les dyspnées aigues du sujet âgé, dans un service d'accueil des urgences (SAU). Résultats préliminaires [résumé]. Réanimation 2001; 10: 96.
  3. Lien CT, Gillespie ND, Struthers AD, Mc Murdo ME. Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail 2002; 4: 91-8.
  4. Mc Cullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003; 10: 198-204.
  5. Mc Namara RM, Gionni DJ. Utility of the peak expiratory flow rate in the differentiation of acute dyspnea. Chest 1992; 101: 129-32.
  6. Harlan WR, Oberman A, Grimm R et al. Chronic congestive heart failure in coronary artery disease: clinical criteria. Ann Intern Med 1977; 86: 133-8.
  7. Lucas G, Triboulloy C. L'insuffisance cardiaque du sujet âgé. La revue de gériatrie 2002; 25: 48-90.
  8. Melbye H, Dale K. Inter observervariability in the radiographicdiagnosis of adult out patient pneumonia. Acta Radiol 1992; 33: 79-81.
  9. Jones J, Srodulsky ZM, Romisher S. The aging electrocardiogram. Am J Emerg Med 1990; 8: 240-5.
  10. Begin P, Grassino A. Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive pulmonary disease. Am Rev Resp Dis 1991; 143: 905-12.
  11. Smyrinos NA, Irwin RS. Wheeze and cough in the elderly in: Malher DA, Ed Pulmonary disease in elderly. New York: Mercel Dekker 1993: 113-57.
  12. Rello J Moran JL, Green R, Homn SD et al. Acute exacerbations of chronic obstructive pulmonary disease and mechanical ventilation: a reevaluation. Crit Care Med 1998; 26: 71-8.
  13. Enright PL, Mc Clelland RL, Newman AB, et al. Under diagnosis and under treatment of asmtha in the elderly. Chest 1999; 116: 603-13.
  14. Giraud V, Ameille J, Chinet T. Epidemiology of COPD in France.Presse Med. 2008; 37(3 Pt 1): 377-84.
  15. Similowski T, Boucot I, Piperno D et al. Chronic obstructive pulmonary disease in france: the patients perspective. Results of an international survey (confronting COPD). Press Med 2003; 32: 1403-9.
  16. Yap LB. B-type natriuretic peptide and the right heart. Heart Fail Rev. 2004;9: 99-105.
  17. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B- natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol2002; 39: 202-9.
  18. Dickstein K, Cohen-Solal A, Filippatos G, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Eur Heart J 2008; 29: 2388-442.
  19. Jourdain P, Funck F, Canault E, et al. Value of type B natriuretic peptide in the emergency management of patients with suspected cardiac failure. Report of 125 cases. Arch Mal Coeur Vaiss 2002; 95: 763-7.
  20. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of Bnatriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am J Heart 2001; 141: 367-74.
  21. Jourdain P, Cohen-Solal A, Cosson S, Et al. La prise en charge de l'insuffisant cardiaque âgé. ICC 2009; 11: 12-16.
  22. Fleisher D, Espiner AE, Yandle TG, et al. Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea. N.Z. Med J 1997; 110: 71-4.
  23. Januzzi Jr. JL, Richards MR. An international consensus statement regarding amino-terminal Pro-B-type natriuretic peptide testing: the international NT-proBNP consensus panel. Am J Cardiol 2008; 101: 1-96.
  24. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330-7
  25. Logeart D, Saudubray C, Beyne P, et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 2002; 40: 1794-800.
  26. Villacorta H, Duarte A, Duarte NM, et al. The role of B-type natriuretic peptide in the diagnosis of congestive heart failure in patients presenting to an emergency department with dyspnea. Arq Bras Cardiol 2002; 79: 564-72.
  27. Cowie MR, StruthersAD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.
  28. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of Bnatriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am CollCardiol 2001; 37: 379-85.
  29. Ray p, Lefort y, El Achkar R, Riou B. Intérêt du dosage du peptide natriurétique de type-B en médecine d'urgence. Réanimation 2003 ; 12: 475-81.
  30. Damien Logeart et al. Insuffisance cardiaque et dosage du BNP en pratique clinique. Spectra Biologie 2007; 157: 37-41.
  31. Baggish AL, Cameron R, Anwaruddin S, et al. A Clinical and Biochemical Critical Pathway for the Evaluation of Patients with Suspected Acute Congestive Heart Failure: The Pro BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Algorithm. Crit Pathw Cardiol. 2004; 3:171-6.
  32. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system. J Clin Invest 1991; 87: 1402-12.
  33. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-8.
  34. Fauvel JP. BNP et NT- pro-BNP en Insuffisance cardiaque et rénale.JNC 2009; 54: 134-46.
  35. Gutierrez OM, Tamez H, Bhan I et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem 2008; 54: 1339-48.
  36. Lapoint J, Viet Lê VH. Dosage du NT-pro BNP: Brève expérience clinique à l'hôpital Maisonneuve-Rosemont. Ann Biol Clin Qué 2007; 44: 7-12.
  37. Jourdain P, Lefèvre G, Oddoze C, et al. NT-proBNP en pratique « De la biologie à la clinique ». Ann Biol Clin 2009; 67: 255- 71.
  38. Ababsa R, Jourdain P, Funck P, Deschamps P, Sadeg N.BNP et dyspnée : proposition d'une stratégie diagnostiquebasée sur deux seuils décisionnels de BNP. Ann Biol Clin 2005; 63: 213-6.
  39. Muller Ch, Scholer A, Laule-Kilian K, et al. Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea. N Engl J Med 2004; 350: 647-54.
  40. Siebert U, Januzzi Jr. JL, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 2006; 98: 800-5.
  41. Moe GW, Howlett J, Januzzi JL, Zowall H, Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115: 3103-10.